Home » Newsletters » BioWorld

BioWorld

Oct. 8, 1993

View Archived Issues

PATENTS OF NOTE

SERAGEN'S CLINICAL TRIAL RESULTS PUBLISHED

BIO ENDORSES NAFTA

CELL IMPLANTS DELIVER NGF TO PRIMATE BRAINS

MOUSE MODEL IMPLICATES IL-4 IN AIDS

MEDAREX ANTIBODY ELICITS IMMUNE RESPONSE

CYTOTHERAPEUTICS COMPLETES PRIVATE FINANCING

TWO COMPANIES JOIN COLORADO CENTER

CEPHALON DISCOVERS INHIBITORS FOR ALZHEIMER'S

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...